0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      High prevalence of human T‐cell leukemia virus type‐1b genotype among blood donors in Gabon, Central Africa

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          BACKGROUND

          The African continent is considered to be the largest endemic area of HTLV‐1 infection, with at least several million infected individuals. Systematic screening of blood donors can prevent the transmission of HTLV‐1 in blood. Gabon is one of the countries with the highest prevalence of HTLV‐1 worldwide, and yet the routine testing of blood donors has still not been introduced.

          METHODS

          All blood donations collected between April and July 2017 at the Centre National de Transfusion Sanguine of Gabon were studied. Plasma samples were screened by ELISA for the presence of HTLV‐1/2 antibodies. Western blot (WB) and polymerase chain reaction (PCR) tests were used for confirmation.

          RESULTS

          In total, 3123 blood donors were tested, including 1740 repeat and 1378 first‐time blood donors (FTBDs). Of them, 132 samples tested positive for HTLV‐1/2 by ELISA (4.2%). WB and PCR confirmed HTLV‐1 infection for 23 individuals. The overall prevalence of HTLV‐1 was 0.74% [95% CI 0.47%‐1.10%], 1% in FTBD, and 0.5% in repeat donors. Age and sex‐adjusted prevalence was five‐fold lower in FTBD than in the general adult population of rural areas of Gabon. All detected HTLV‐1 strains belonged to the central African HTLV‐1b genotype but were highly diverse.

          CONCLUSION

          We report an overall prevalence of HTLV‐1 of 0.74%, one of the highest values reported for blood donors in Africa. Given the high risk of HTLV‐1 transmission in blood, it is necessary to conduct cost‐effectiveness studies to determine the need and feasibility of implementing screening of HTLV‐1 in blood donors in Gabon.

          Related collections

          Most cited references40

          • Record: found
          • Abstract: found
          • Article: not found

          HTLV-1-associated myelopathy/tropical spastic paraparesis.

          Human T-lymphotropic virus 1 (HTLV-1)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) is a progressive disease of the CNS that causes weakness or paralysis of the legs, lower back pain and urinary symptoms. HAM/TSP was first described in Jamaica in the nineteenth century, but the aetiology of the condition, infection with the retrovirus HTLV-1, was only identified in the 1980s. HAM/TSP causes chronic disability and, accordingly, imposes a substantial health burden in areas where HTLV-1 infection is endemic. Since the discovery of the cause of HAM/TSP, considerable advances have been made in the understanding of the virology, immunology, cell biology and pathology of HTLV-1 infection and its associated diseases. However, progress has been limited by the lack of accurate animal models of the disease. Moreover, the treatment of HAM/TSP remains highly unsatisfactory: antiretroviral drugs have little impact on the infection and, although potential disease-modifying therapies are widely used, their value is unproved. At present, clinical management is focused on symptomatic treatment and counselling. Here, we summarize current knowledge on the epidemiology, pathogenesis and treatment of HAM/TSP and identify areas in which further research is needed. For an illustrated summary of this Primer, visit: http://go.nature.com/tjZCFM.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Establishment of the milk-borne transmission as a key factor for the peculiar endemicity of human T-lymphotropic virus type 1 (HTLV-1): the ATL Prevention Program Nagasaki

            In late 2010, the nation-wide screening of pregnant women for human T-lymphotropic virus type 1 (HTLV-1) infection was implemented in Japan to prevent milk-borne transmission of HTLV-1. In the late 1970s, recognition of the adult T-cell leukemia (ATL) cluster in Kyushu, Japan, led to the discovery of the first human retrovirus, HTLV-1. In 1980, we started to investigate mother-to-child transmission (MTCT) for explaining the peculiar endemicity of HTLV-1. Retrospective and prospective epidemiological data revealed the MTCT rate at ∼20%. Cell-mediated transmission of HTLV-1 without prenatal infection suggested a possibility of milk-borne transmission. Common marmosets were successfully infected by oral inoculation of HTLV-1 harboring cells. A prefecture-wide intervention study to refrain from breast-feeding by carrier mothers, the ATL Prevention Program Nagasaki, was commenced in July 1987. It revealed a marked reduction of HTLV-1 MTCT by complete bottle-feeding from 20.3% to 2.5%, and a significantly higher risk of short-term breast-feeding (<6 months) than bottle-feeding (7.4% vs. 2.5%, P < 0.001).
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Donor testing and risk: current prevalence, incidence, and residual risk of transfusion-transmissible agents in US allogeneic donations.

              Over the past 20 years, there has been a major increase in the safety of the blood supply, as demonstrated by declining rates of posttransfusion infection and reductions in estimated residual risk for such infections. Reliable estimates of residual risk have been possible within the American Red Cross system because of the availability of a large amount of reliable and consistent data on donations and infectious disease testing results. Among allogeneic blood donations, the prevalence rates of infection markers for hepatitis C virus (HCV) and hepatitis B virus have decreased over time, although rates for markers of human immunodeficiency virus (HIV) and human T-cell lymphotropic virus did not. The incidence (/100 000 person-years) of HIV and HCV among repeat donors showed apparent increases from 1.55 and 1.89 in 2000 through 2001 to 2.16 and 2.98 in 2007 through 2008. These observed fluctuations confirm the need for continuous monitoring and evaluation. The residual risk of HIV, HCV, and human T-cell lymphotropic virus among all allogeneic donations is currently below 1 per 1 million donations, and that of hepatitis B surface antigen is close to 1 per 300 000 donations. Copyright © 2012 Elsevier Inc. All rights reserved.
                Bookmark

                Author and article information

                Contributors
                jill.lea.ramassamy@pasteur.fr
                agessain@pasteur.fr
                Journal
                Transfusion
                Transfusion
                10.1111/(ISSN)1537-2995
                TRF
                Transfusion
                John Wiley & Sons, Inc. (Hoboken, USA )
                0041-1132
                1537-2995
                15 May 2020
                July 2020
                : 60
                : 7 ( doiID: 10.1111/trf.v60.7 )
                : 1483-1491
                Affiliations
                [ 1 ] Unité dʼEpidémiologie et Physiopathologie des Virus Oncogènes, Département de Virologie Institut Pasteur, UMR 3569, CNRS Paris France
                [ 2 ] Université de Paris Paris France
                [ 3 ] Unité des infections rétrovirales et pathologies associées Centre International de Recherches Médicales de Franceville Franceville Gabon
                [ 4 ] Ecole Doctorale Régionale dʼAfrique Centrale, Infectiologie Tropicale Franceville Gabon
                [ 5 ] Centre National de Transfusion sanguine (CNTS) Libreville Gabon
                Author notes
                [*] [* ] Address reprint requests to: Jill‐Léa Ramassamy, Institut Pasteur, Unité dʼEpidémiologie et Physiopathologie des Virus Oncogènes, 28 Rue du Dr. Roux, F‐75015 Paris, France; e‐mail: jill.lea.ramassamy@ 123456pasteur.fr ;

                Antoine Gessain, Institut Pasteur, Unité dʼEpidémiologie et Physiopathologie des Virus Oncogènes, 28 Rue du Dr. Roux, F‐75015 Paris, France; e‐mail: agessain@ 123456pasteur.fr

                [†]

                These authors contributed equally to this work.

                Author information
                https://orcid.org/0000-0003-2006-2236
                https://orcid.org/0000-0001-5331-6357
                https://orcid.org/0000-0001-6840-4413
                Article
                TRF15838
                10.1111/trf.15838
                7496943
                37dda9f1-842e-4c7d-af92-dc0f0cf5f1d4
                © 2020 The Authors. Transfusion published by Wiley Periodicals LLC on behalf of AABB.

                This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

                History
                : 23 August 2019
                : 26 February 2020
                : 22 March 2020
                Page count
                Figures: 3, Tables: 4, Pages: 9, Words: 6157
                Funding
                Funded by: Agence Nationale de la Recherche , open-funder-registry 10.13039/501100001665;
                Award ID: LabEx ANR10‐LBX‐62 IBEID
                Funded by: Centre National de la Recherche Scientifique , open-funder-registry 10.13039/501100004794;
                Award ID: UMR 3569
                Funded by: European Commission , open-funder-registry 10.13039/501100000780;
                Award ID: FOOD/2016/379‐660
                Categories
                Donor Infectious Disease Testing
                Donor Infectious Disease Testing
                Custom metadata
                2.0
                July 2020
                Converter:WILEY_ML3GV2_TO_JATSPMC version:5.9.0 mode:remove_FC converted:11.09.2020

                Hematology
                Hematology

                Comments

                Comment on this article